orion.fi

Project leader

 
Ari Koivisto
Principal Research Scientist, In Vitro Biology, Turku
PhD
Phone +358 50 966 7731
Fax +358 10 426 7403
E-Mail  

 

Project staff

 
Hugh Chapman
Research Scientist, In Vitro Biology, Turku
MSc
Phone +358 10 426 7455
Fax +358 10 426 7403
E-Mail  

 

 
Satu Juhila
Research Scient, In Vitro Biology, Espoo
PhD
Phone +358 50 966 5751
E-Mail  

 

 
Tuula Lähteenmäki
Research Scientist, In Vitro Biology, Espoo.
PhD
Phone +358 10 426 4574
E-Mail  

 

 
Marja Rantanen
Research Scientist, In Vitro Biology, Turku
MSc
Phone +358 10 426 7106
Fax +358 10 426 7403
E-Mail  

 

 
Emani Maheswara
Research Scientist, In Vitro Biology, Turku
PhD
Phone +358 10 426 7422
Fax +358 10 426 7403
E-Mail  

 


Institute presentation

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion’s net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion’s A and B shares are listed on NASDAQ OMX Helsinki.